- Epidemiology of TB, MDR-TB, XDR-TB and TB/HIV; social determinants.
- Perspectives of the National Tuberculosis Program (NTP) on implementing innovative diagnostics and treatment for M/XDRTB.
- Laboratory diagnosis of TB and TB drug resistance; TB diagnostic algorithm proposed by the European TB Laboratory Initiative (ELI).
- Programmatic approach to the treatment of rifampicin-resistant TB (RR-TB); the role of clinicians in the introduction of new and repurposed drugs and regimens for different types of resistance.
- Clinical issues in new drug introduction, regimen design, and drug-drug interactions; off-label use of new TB drugs; use in special populations.
- Role of patient-centred care, support and adherence-support package; ethical considerations and informed consent; examples of patient consent.
- Adjuvant therapies; the role of surgery using new and re-purposed drugs.
- Drug safety; scope of safety data collection and definitions; active drug safety monitoring and management (aDSM).
- Clinical management of adverse events of interest: peripheral neuropathy, myelosuppression, prolonged QT interval, optic nerve disorder (optic neuritis), hepatitis, acute kidney injury, hearing impairment, hypokalemia, and hypothyroidism.
- Monitoring and evaluation requirements for the use of new and re-purposed drugs; length of therapy with new drugs.
- Pharmacokinetic and minimum inhibitory concentration (MIC) variability as determinants of TB clinical outcomes in adults and children - state of the evidence.
Clinicians, staff of the national TB programs, responsible for diagnostics and treatment of DR-TB, from countries with high level DR-TB
Duration and language
5 business days (from Monday to Friday)
Currently course is available in Russian language
1200 EUR, including training materials, site visit, local transport, catering during working hours/on working days, visa support
hotel accommodation (from ~ 40 EUR to ~ 80 EUR per night), international flight, visa, reduced per diem